Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 109-112, 2010.
Article
in Zh
| WPRIM
| ID: wpr-247582
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To analyze antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis.</p><p><b>METHODS</b>104 patients of hepatitis B virus-related cirrhosis with no previous history of antiviral therapy were treated with entecavir 0.5 mg once daily. 37 patients were taken hepatic histologic examination before and after the treatment.</p><p><b>RESULTS</b>Mean reductions of serum HBV DNA was 5.1 log10 96 weeks after the treatment, HBV DNA became undetectable in 98.1% patients, and ALT became normal in 80.7% patients; HBeAg seroconversion occurred in 13.9% of the 72 HBeAg positive patients; 61.5% of these patients were infected with genotype C HBV, and 26.9% were infected with genotype B HBV. The genotype of HBV was not associated with the therapeutical effect. Child-pugh score was associated with the progression of the disease: the proportion of patients with disease progression was highest in Child-Pugh C grade patients and lowest in Child-Pugh A grade patients. The level of the HBV DNA load was positively correlated with Knodell HAI score at the baseline and 96 weeks after the treatment.</p><p><b>CONCLUSION</b>Entecavir treatment results in suppression of HBV replication and delayed progression of fibrosis in patients with hepatitis B virus-related cirrhosis.</p>
Full text:
1
Index:
WPRIM
Main subject:
Antiviral Agents
/
Time Factors
/
Virology
/
Virus Replication
/
Blood
/
DNA, Viral
/
Hepatitis B virus
/
Treatment Outcome
/
Hepatitis B, Chronic
/
Therapeutic Uses
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Zh
Journal:
Chinese Journal of Hepatology
Year:
2010
Type:
Article